-
公开(公告)号：US20210100805A1
公开(公告)日：2021-04-08
申请号：US16880871
申请日：2020-05-21
发明人： Vivek Saroj Kumar Chopra , Jorge DiMartino , Laurie A. Kenvin , Robert Douglas Knight , Kyle MacBerth , Krishnan Viswanadhan , Qiang Xu , Samuel V. Agresta
IPC分类号： A61K31/53 , A61K31/7068 , A61P35/02
摘要： Provided are methods and compositions for treating cancers in patients carrying an IDH2 mutation using a combination of an inhibitor of a mutant IDH2 enzyme and a DNA demethylating agent.
-
公开(公告)号：US20180296583A1
公开(公告)日：2018-10-18
申请号：US15767822
申请日：2016-10-14
发明人： Samuel V. Agresta , Krishnan Viswanadhan , Jorge DiMartino , Vivek Saroj Kumar Chopra , Kyle J. MacBeth , Robert Douglas Knight , Laurie Kenvin , Qiang Xu
IPC分类号： A61K31/706 , A61P35/02 , A61K31/444
摘要： Provided are methods and compositions for treating cancers in patients carrying an IDH1 mutation using a combination of an inhibitor of a mutant IDH1 enzyme and a DNA demethylating agent.
-
公开(公告)号：US10695352B2
公开(公告)日：2020-06-30
申请号：US15768462
申请日：2016-10-14
发明人： Vivek Saroj Kumar Chopra , Jorge DiMartino , Laurie A. Kenvin , Robert Douglas Knight , Kyle MacBeth , Krishnan Viswanadhan , Qiang Xu , Samuel V. Agresta
IPC分类号： A61K31/53 , A61K31/7068 , A61P35/02 , A61K31/706
摘要： Provided are methods and compositions for treating cancers in patients carrying an IDH2 mutation using a combination of an inhibitor of a mutant IDH2 enzyme and a DNA demethylating agent.
-
公开(公告)号：US10653710B2
公开(公告)日：2020-05-19
申请号：US15767822
申请日：2016-10-14
发明人： Samuel V. Agresta , Krishnan Viswanadhan , Jorge DiMartino , Vivek Saroj Kumar Chopra , Kyle J. MacBeth , Robert Douglas Knight , Laurie Kenvin , Qiang Xu
IPC分类号： A61K31/706 , A61K31/444 , A61K45/06 , A61K35/02 , A61P35/02
摘要： Provided are methods and compositions for treating hematological malignancies in patients carrying an IDH1 mutation using a combination of an inhibitor of mutant IDH1 enzyme, (S)-N-((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide, or a pharmaceutically acceptable salt thereof (COMPOUND 2) and a DNA demethylating agent.
-
公开(公告)号：US20180303840A1
公开(公告)日：2018-10-25
申请号：US15768462
申请日：2016-10-14
发明人： Vivek Saroj Kumar Chopra , Jorge DiMartino , Laurie A. Kenvin , Robert Douglas Knight , Kyle MacBeth , Krishnan Viswanadhan , Qiang Xu , Samuel V. Agresta
摘要： Provided are methods and compositions for treating cancers in patients carrying an IDH2 mutation using a combination of an inhibitor of a mutant IDH2 enzyme and a DNA demethylating agent.
-
公开(公告)号：US09101579B2
公开(公告)日：2015-08-11
申请号：US14079497
申请日：2013-11-13
申请人： Celgene Corporation
IPC分类号： A61K38/15 , A61K45/06 , A61K31/517
CPC分类号： A61K38/15 , A61K31/437 , A61K31/4412 , A61K31/517 , A61K45/06 , A61K31/44
摘要： Provided herein are methods of treating cancer in a cancer patient by overcoming resistance of a cancer cell to a drug, or methods of overcoming resistance of a cancer cell to a drug, comprising administering to the patient an effective amount of (i) an EGFR tyrosine kinase inhibitor or a B-Raf kinase inhibitor, and (ii) an HDAC inhibitor. Also provided are methods for inhibiting or preventing proliferation of drug tolerant persister (DTP) cells comprising contacting these cells with an EGFR tyrosine kinase inhibitor or B-Raf kinase inhibitor in combination with an HDAC inhibitor. Yet also provided are methods for inhibiting or preventing formation of colonies of drug tolerant expanded persister (DTEP) cells comprising contacting these cells with an EGFR tyrosine kinase inhibitor or B-Raf kinase inhibitor in combination with an HDAC inhibitor.
摘要翻译： 本文提供了通过克服癌细胞对药物的抗性或克服癌细胞对药物的抗性的方法来治疗癌症患者中的癌症的方法，包括向患者施用有效量的（i）EGFR酪氨酸 激酶抑制剂或B-Raf激酶抑制剂，和（ii）HDAC抑制剂。 还提供了用于抑制或预防耐受性持久性细胞（DTP）细胞增殖的方法，包括将这些细胞与EGFR酪氨酸激酶抑制剂或B-Raf激酶抑制剂与HDAC抑制剂组合接触。 还提供了用于抑制或预防形成药物耐受扩张的持续性（DTEP）细胞的集落的方法，包括将这些细胞与EGFR酪氨酸激酶抑制剂或B-Raf激酶抑制剂与HDAC抑制剂组合接触。
-
公开(公告)号：US20130109644A1
公开(公告)日：2013-05-02
申请号：US13665778
申请日：2012-10-31
申请人： Celgene Corporation
IPC分类号： A61K31/706 , A61P35/00
CPC分类号： A61K31/282 , A61K31/337 , A61K31/7042 , A61K31/7052 , A61K31/706 , A61K31/7064 , A61K31/7068 , A61K45/06 , A61K47/643 , A61K2300/00
摘要： Provided herein are methods for treating subjects having a cancer, such as a relapsed or refractory solid tumor, wherein the method comprises administering to the subject a cytidine analog. In certain of the methods, the cytidine analog is administered alone or in combination with one or more anti-cancer agents. Also provided are methods for using a cytidine analog, to treat diseases and disorders including disorders related to abnormal cell proliferation, hematologic disorders, and immune disorders, among others. In certain of the methods, the cytidine analog is formulated in an oral dosage form and administered orally.
-
8.发明授权公开(公告)号：US09125884B2
公开(公告)日：2015-09-08
申请号：US13665778
申请日：2012-10-31
申请人： Celgene Corporation
IPC分类号： A01N43/04 , A61K31/70 , A61K31/282 , A61K31/706 , A61K31/7052 , A61K31/7042 , A61K31/337 , A61K31/7068 , A61K45/06
CPC分类号： A61K31/282 , A61K31/337 , A61K31/7042 , A61K31/7052 , A61K31/706 , A61K31/7064 , A61K31/7068 , A61K45/06 , A61K47/643 , A61K2300/00
摘要： Provided herein are methods for treating subjects having a cancer, such as a relapsed or refractory solid tumor, wherein the method comprises administering to the subject a cytidine analog. In certain of the methods, the cytidine analog is administered alone or in combination with one or more anti-cancer agents. Also provided are methods for using a cytidine analog, to treat diseases and disorders including disorders related to abnormal cell proliferation, hematologic disorders, and immune disorders, among others. In certain of the methods, the cytidine analog is formulated in an oral dosage form and administered orally.
摘要翻译： 本文提供了治疗患有癌症的受试者（例如复发性或难治性实体瘤）的方法，其中所述方法包括给予受试者胞苷类似物。 在某些方法中，胞苷类似物单独施用或与一种或多种抗癌剂组合施用。 还提供了使用胞苷类似物治疗疾病和病症的方法，包括与异常细胞增殖相关的疾病，血液病症和免疫疾病等。 在某些方法中，胞苷类似物以口服剂型配制并口服给药。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.028 秒)
